SF3B1 and myelodysplastic syndrome: However, patients with mutations in SRSF2 and U2AF1 have been shown to have an adverse outcome in MDS and AML (38, 75–77), while others showed no significant prognostic impact of mutations in U2AF1, ZRSR2, and SF3B1 on patients’ outcome (78).